Novel Vanillic Acid-Loaded In Situ Gels: Development, Characterization, In Vitro Evaluation for Enhanced Wound Healing and Skin Irritation Test.

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Gökçe Mutlu Sonat, Emre Şefik Çağlar, Dilara Güreşçi, Ahmet Aydın, Hande Sipahi, Neslihan Üstündağ Okur
{"title":"Novel Vanillic Acid-Loaded <i>In Situ</i> Gels: Development, Characterization, <i>In Vitro</i> Evaluation for Enhanced Wound Healing and Skin Irritation Test.","authors":"Gökçe Mutlu Sonat, Emre Şefik Çağlar, Dilara Güreşçi, Ahmet Aydın, Hande Sipahi, Neslihan Üstündağ Okur","doi":"10.1080/10837450.2025.2534867","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to develop <i>in situ</i> gel formulations containing vanillic acid to enhance patient compliance and accelerate wound healing. Vanillic acid-loaded <i>in situ</i> gels were prepared and their physicochemical properties were evaluated through <i>in vitro</i> release and <i>ex vivo</i> permeation studies. Additionally, antioxidant capacity, cytotoxicity, wound healing, prostaglandin E2 levels, IL-6 inhibition and skin irritation tests were conducted. The optimized IN3-VA formulation exhibited a gelling temperature of 32.394 ± 0.842, a pH value of 4.780 ± 0.010 and a viscosity of 2473.33 ± 11.54 cP. It demonstrated specific mechanical properties, including hardness of 27.94 ± 1.30 g and adhesiveness of -97.00 ± 14.60 g.mm. The IN15-VA formulation showed improved parameters, with a hardness of 38.84 ± 3.33 g, adhesiveness of -126.35 ± 22.78 g.mm, pH value of 4.870 ± 0.010, viscosity of 3853.33 ± 30.55 cP and a gelling temperature of 31.854 ± 0.345. Both formulations demonstrated sustained release behavior, releasing 60% of the medication <i>in vitro</i> over 6 hours with no cytotoxic effects. They also decreased copper ion reduction and the release of nitric oxide, with cellular proliferation rates of 63% for IN3-VA and 73% for IN15-VA. Moreover, IN15-VA significantly reduced prostaglandin E2 levels, controlled IL-6 increase and exhibited non-irritating properties. The results suggest that these vanillic acid-loaded <i>in situ</i> gels hold promising potential in wound treatment due to their sustained release over 48 hours.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1-25"},"PeriodicalIF":2.6000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Development and Technology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10837450.2025.2534867","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

This study aimed to develop in situ gel formulations containing vanillic acid to enhance patient compliance and accelerate wound healing. Vanillic acid-loaded in situ gels were prepared and their physicochemical properties were evaluated through in vitro release and ex vivo permeation studies. Additionally, antioxidant capacity, cytotoxicity, wound healing, prostaglandin E2 levels, IL-6 inhibition and skin irritation tests were conducted. The optimized IN3-VA formulation exhibited a gelling temperature of 32.394 ± 0.842, a pH value of 4.780 ± 0.010 and a viscosity of 2473.33 ± 11.54 cP. It demonstrated specific mechanical properties, including hardness of 27.94 ± 1.30 g and adhesiveness of -97.00 ± 14.60 g.mm. The IN15-VA formulation showed improved parameters, with a hardness of 38.84 ± 3.33 g, adhesiveness of -126.35 ± 22.78 g.mm, pH value of 4.870 ± 0.010, viscosity of 3853.33 ± 30.55 cP and a gelling temperature of 31.854 ± 0.345. Both formulations demonstrated sustained release behavior, releasing 60% of the medication in vitro over 6 hours with no cytotoxic effects. They also decreased copper ion reduction and the release of nitric oxide, with cellular proliferation rates of 63% for IN3-VA and 73% for IN15-VA. Moreover, IN15-VA significantly reduced prostaglandin E2 levels, controlled IL-6 increase and exhibited non-irritating properties. The results suggest that these vanillic acid-loaded in situ gels hold promising potential in wound treatment due to their sustained release over 48 hours.

新型香草酸负载原位凝胶:开发,表征,体外评估促进伤口愈合和皮肤刺激试验。
本研究旨在开发含有香草酸的原位凝胶配方,以提高患者的依从性并加速伤口愈合。制备了负载香草酸的原位凝胶,并通过体外释放和体外渗透研究对其理化性质进行了评价。此外,还进行了抗氧化能力、细胞毒性、伤口愈合、前列腺素E2水平、IL-6抑制和皮肤刺激试验。优化后的IN3-VA胶凝温度为32.394±0.842,pH值为4.780±0.010,黏度为2473.33±11.54 cP,硬度为27.94±1.30 g,黏性为-97.00±14.60 g.mm。IN15-VA配方参数得到改善,硬度为38.84±3.33 g,粘连性为-126.35±22.78 g。mm, pH值4.870±0.010,粘度3853.33±30.55 cP,胶凝温度31.854±0.345。两种制剂均表现出缓释行为,在体外释放60%的药物超过6小时,无细胞毒性作用。它们还减少了铜离子的还原和一氧化氮的释放,IN3-VA的细胞增殖率为63%,IN15-VA的细胞增殖率为73%。此外,IN15-VA显著降低前列腺素E2水平,控制IL-6的增加,并表现出无刺激性。结果表明,这些负载香草酸的原位凝胶由于其持续释放超过48小时,在伤口治疗中具有很大的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
2.90%
发文量
82
审稿时长
1 months
期刊介绍: Pharmaceutical Development & Technology publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems, emphasizing practical solutions and applications to theoretical and research-based problems. The journal aims to publish significant, innovative and original research to advance the frontiers of pharmaceutical development and technology. Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as: -Preformulation and pharmaceutical formulation studies -Pharmaceutical materials selection and characterization -Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation -QbD in the form a risk assessment and DoE driven approaches -Design of dosage forms and drug delivery systems -Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies -Drug delivery systems research and quality improvement -Pharmaceutical regulatory affairs This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信